Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Larson Financial Group LLC

Larson Financial Group LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,476 shares of the biopharmaceutical company’s stock after acquiring an additional 2,271 shares during the period. Larson Financial Group LLC’s holdings in Gilead Sciences were worth $1,286,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. FMR LLC grew its position in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock valued at $3,293,822,000 after buying an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock worth $2,608,337,000 after buying an additional 749,047 shares during the period. Norges Bank purchased a new position in shares of Gilead Sciences during the fourth quarter worth about $1,789,254,000. Finally, Northern Trust Corp grew its holdings in shares of Gilead Sciences by 19.7% during the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after buying an additional 2,458,954 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD opened at $109.06 on Wednesday. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 52-week low of $70.33 and a 52-week high of $119.96. The company has a 50-day simple moving average of $108.15 and a 200-day simple moving average of $104.91. The company has a market capitalization of $135.66 billion, a PE ratio of 22.96, a P/E/G ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period in the prior year, the business posted ($1.32) earnings per share. The firm’s revenue for the quarter was down .3% compared to the same quarter last year. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date was Friday, June 13th. Gilead Sciences’s dividend payout ratio is currently 66.53%.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the transaction, the insider directly owned 121,152 shares of the company’s stock, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the sale, the chief financial officer directly owned 165,110 shares in the company, valued at $18,190,168.70. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,000 shares of company stock valued at $6,623,445. Company insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. Morgan Stanley upped their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. Oppenheimer cut their price target on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price objective on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $111.38.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.